MedTrace Logo

Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

NCT03137082 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-06-05

Study results available
· View outcomes & findings →

Summary

Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.

Conditions

  • Alcohol Abstinence

Interventions

DRUG

Guanfacine XR 3mgs/daily

Guanfacine 3mg tablet

DRUG

Placebo (for guanfacine)

Sugar pill manufactured to mimic guanfacine tablets

Sponsors & Collaborators

Principal Investigators

  • Helen C Fox, PhD · Stony Brook University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-12
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03137082 on ClinicalTrials.gov